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The biggest health issues in the world nowadays are 
cardiovascular disease (CVD). Disorders in 
cardiovascular include conditions such as Coronary 
Heart Disease (CHD), Heart Failure, and Stroke. 
Cardiovascular disease is part of the Non-
Communicable Diseases (NCD) and has surpassed 
cancer as the leading cause of death worldwide. Using 
data from the World Health Organization (WHO) in 
2015, it was said that 31% of 56.5 million deaths in the 
world were caused by cardiovascular disease. Some of 
them are CHD and stroke with 42.3% and 38.3%, 
respectively. Deaths from heart disease occur in several 
countries, ranging from low-income to high-income 
countries. Indonesia is one of the developing countries 
with a high cardiovascular disease mortality rate (WHO, 
2012). 
In general, coronary heart disease can be divided into 
two, namely acute coronary syndrome and chronic 
coronary syndrome. The prevalence of CHD in 
Indonesia is still quite high, as evidenced by data 
submitted by the Basic Health Research by the Ministry 
of Health in 2014 showing the number of CHD patients 
in East Java based on a doctor's diagnosis by 0.5%, 
while based on symptoms and a doctor's diagnosis by 
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Introduction: Clopidogrel is the most widely prescribed antiplatelet for patients 
with coronary heart disease (CHD) who cannot take aspirin. Despite its 
effectiveness, Clopidogrel has several side effects caused by its metabolite. 
Clopidogrel resistance has been identified in some patients, and patient factors 
such as genetic polymorphisms in CYP2C19 may play a role in this resistance. The 
researchers wanted to look at CYP2C19*3 polymorphisms and platelet 
aggregation in CHD patients who were taking clopidogrel.    Methods: This 
research used a cross-sectional design. The research enrolled CHD patients at a 
local hospital's cardiology unit with certain inclusion and exclusion requirements. 
In the clinical laboratory, CYP2C19*3 polymorphisms was investigated using 
polymerase chain reaction (PCR), and platelet aggregation will be measured using 
light transmission aggregometry (LTA).     Results: This research enlisted the 
participation of 53 patients. The majority of the patients (68%) were men, with 
the highest age group being 60-69 years old. The most common comorbid 
disorder was hypertension. The result of CYP2C19*3 polymorphisms as follows: 
GA (75%), AA (21%), and GG (4%). Hypo-aggregation (89%) and normal-
aggregation (89%) are seen in the majority of patients (11%). The authors were 
unable to locate the patient who had hyper-aggregation.      Conclusion: According 
to descriptive research, CYP2C19*3 polymorphisms caused hypo-aggregation in 
more patients than normal aggregation in this study. 
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The accumulation of atherosclerotic plaque in the 
endothelial walls of coronary arteries causes CHD. 
Plaque builds up on artery walls, reducing the blood 
flow that carries nutrients and oxygen. Ischemic 
symptoms are reported by CHD patients due to an 
imbalance in oxygen supply and demand. The goal of 
CHD therapy is to keep the plaque in the patient's 
coronary arteries stable by inhibiting the progression of 
atherosclerotic plaque and preventing plaque that is 
formed from rupture (Montalescot, 2013). 
One of the treatments for CHD patients is antiplatelet 
therapy. In CHD patients, antiplatelet therapy helps to 
avoid or minimize platelet aggregation and/or plaque 
formation. Reduced platelet aggregation and/or plaque 
formation lowers the risk of thrombus in blood vessels, 
thus lowers the risk of ischemia, which can further lead 
to ischemic cardiovascular events. Clopidogrel is an 
antiplatelet agent that is given as a treatment for 
coronary artery disease in addition to Aspirin. The 
CAPRIE study (Clopidogrel vs Aspirin in Patients at Risk 
of Ischemic Events) shows slightly better effectiveness 
on Clopidogrel compared to Aspirin in preventing 
cardiovascular events in patients with previous 
myocardial infarction, stroke, or peripheral arterial 
disease. 
Clopidogrel's pharmacodynamic effects are dependent 
on factors that affect its metabolism, which is one of its 
drawbacks (Aradi, 2014). Clopidogrel is a prodrug that 
must be oxidized by the cytochrome P450 system in the 
liver to produce active metabolites. Clopidogrel's 
antiplatelet efficacy is determined by 
pharmacodynamic factors linked to drug-metabolising 
enzymes, such as cytochrome P450 classes (for 
example, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP3A4, and CYP3A5) and paraoxonase 1 (PON1).  
About 4-30% of patients treated with Clopidogrel show 
a low antiplatelet response or do not show an 
antiplatelet response. Clopidogrel's efficacy is 
influenced by a number of factors, including the 
patient's age, BMI (Body Mass Index), kidney disease, 
and genetic factors. From the genetic aspect, there are 
various CYP2C19 polymorphism profiles related to the 
metabolic process of the drug, where CYP2C19 is 
responsible for the metabolic activation of Clopidogrel, 
which is a prodrug to be transformed into active 
metabolites and loss-of-function alleles CYP2C19, 
which is directly related to the recurrence of 
cardiovascular disorders in patients receiving 
Clopidogrel. Clopidogrel resistance, or non-responsive 
Clopidogrel, is the term for this phenomenon. These 
patients, according to prior reports, have a higher risk 
of ischemic cardiovascular events.  
CYP2C19*3 and CYP2C19*2 polymorphisms have the 
effect of reducing the effectiveness of Clopidogrel (loss-
of-alleles) active metabolites in the systemic and anti-
aggregation ability. Judging from the genetic 
polymorphism present in CYP2C19, patients treated 
with Clopidogrel can show a varied therapeutic 
response (Yin, 2011). 
It is well known that Clopidogrel is an inactive prodrug 
that requires oxidation by the hepatic cytochrome P450 
system to produce active metabolites. Due to 
mutations in the gene for the CYP enzyme, this can 
affect the effectiveness of Clopidogrel. Of these genes, 
the main focus is CYP2C19. Loss-of-function alleles, 
such as CYP2C19*2 and CYP2C19*3, are responsible for 
decreased activation of Clopidogrel and increased risk 
of recurrent heart disease in CHD patients. 
The prevalence of CYP2C19 loss-of-function 
polymorphisms worldwide is 24% of the non-Hispanic 
white population, 18% of Mexicans, 33% of African 
Americans, and 50% of Asians. This population is a 
homozygous carrier that has a poorly metabolised 
CYP2C19, thereby reducing the antiplatelet effect of 
Clopidogrel (Kitzmiller, 2011). The prevalence of 
CYP2C19 loss-of-function polymorphisms in Asia is 
24.2% of the Japanese population, 14.8% of the Korean 
population, 8.9% of the Han Chinese, 9% of the Malay 
population and 13% of the Indian population. 
Specifically, in Singapore, there are 10% of Chinese-
Singaporean subjects and 9% of Malay-Singaporean 
subjects, and only 1% of Indian-Singaporean subjects 
(Chan, 2012). 
The CYP2C19*3 is a loss-of-function allele, which is 
responsible for decreasing the activation of 
Clopidogrel. Clopidogrel concentrations in plasma are 
lower as a result of reduced clopidogrel activation, 
resulting in hyper platelet aggregation. The risk of 
persistent ischemia increases when hyper platelet 
aggregation occurs. Based on this background, and not 
many studies look at the genetic influence on the 
Clopidogrel metabolism process, the authors intend to 
conduct research by looking at the genetic influence on 
patients using Clopidogrel. The purpose of this study 
was to look at the effect of one of the alleles suspected 
of causing a decrease in the function of Clopidogrel 
(loss of function allele CYP2C19*3 polymorphisms). The 
effect of pharmacodynamic effects of Clopidogrel seen 




A cross-sectional design with descriptive analysis 
methods was used in this study. The aim of this study 
was to look at the relationship between CYP2C19*3 
polymorphisms and platelet aggregation in CHD 
patients who were taking Clopidogrel. 
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Population of the study 
The participants in this study were patients with 
coronary artery disease who received outpatient 
treatment at a local hospital. The sample used is drawn 
from a population that meets the following inclusion 
and exclusion criteria: 
Inclusion criteria: 
1. Patients who are willing to join the study 
2. Patients using generic clopidogrel therapy 
3. Patients who have high adherence to treatment 
4. Patients taking clopidogrel therapy for one month 
Exclusion Criteria: 
1. Patients undergoing chemotherapy 
2. Patients who have liver problems 
Before beginning the study, all participants signed a 
written informed consent form. The local hospital 




The CYP2C19*3 polymorphism profile was analysed by 
the Polymerase Chain Reaction (PCR) method. The 
sample used was a patient's blood sample that DNA 
isolation stages had previously been carried out. PCR is 
used for DNA amplification using specific carrier 
primers. The primers used for CYP2C19*3 DNA 
amplification are primary pairs 5'-
TATTATTATCTGTTAACTAATATGA-3' and 5′-
ACTTCAGGGCTTGGTCAATA-3'. PCR was carried out in 
the following stages: initial denaturation at a 
temperature of 94˚C for 2 minutes. After being 
denatured, it continues with 35 cycles consisting of: 
a. Denaturation at 94˚C for 45 seconds 
b. Annealing at 53 ° C for 40 seconds 
c. Polymerisation at 72 ° C for 30 seconds 
d. Final extension at 72 ° C for 5 minutes 
After 35 cycles, the DNA amplicon is obtained. Followed 
by the digestion process, the CYP2C19*3 DNA amplicon 
was digested with the BamHI restriction enzyme at 
37˚C and a Bovine Serum Albumin (BSA) buffer. 
Deactivation of the enzyme at 65˚C for 20 minutes. The 
next step was to obtain RFLP (Restriction Fragment 
Length Polymorphism) products. The obtained RFLP 
products are then separated in agarose gel solution 
(electrophoresis). The next step was the visualisation of 
electrophoresis results followed by staining in a 
solution of ethidium bromide (5 mg/mL) for ten 
minutes. Then the destaining step was carried out by 
immersing it in a solution of water for five-ten minutes. 
After observing the migration of DNA in the UV lamp 
transilluminator. Then agarose gel which has been 
electrophoresed, and  DNA migration was observed in 
UV transilluminator and then photographed. 
 
Platelet function test 
In this study, the profile of platelet aggregation was 
seen through the Turbidimetry test conducted at the 
Prodia Laboratory. The sample used in this test is 
platelet-rich plasma (PRP) from CHD patients using 
clopidogrel therapy. Platelet aggregation was 
measured in PRP at 37°C by light transmittance 
aggregometry using an aggregometer (Model 700, 
Chrono-Log Corp., USA). The PRP was pre-warmed to 
37°C for five minutes before the addition of the 
agonists, i.e. 5 μM adenosine diphosphate (ADP), 0.5 
mM arachidonic acid (AA) and 2 μg / ml collagen (all 
from Chrono-Log Corp., USA). The aggregation 
response was monitored for at least five minutes, and 
the extent of aggregation was expressed as the 
percentage (%) aggregation calculated using Aggrolink 
software (Chrono-Log Corp., USA) 
 
Results  
This research looked at patients with Coronary Heart 
Disease (CHD) who were taking Clopidogrel as their 
only antiplatelet medication. The study was carried out 
at the District General Hospital's Cardiology Center. A 
total of 53 samples were collected. Table I shows the 
patient characteristics in this report. 
 
Table I: Patient characteristics 





























• Diabetes mellitus 
• Hypertension 
• Dyslipidemia  
• Heart Failure 
• Asthma 
• Chronic Kidney Disease  











Blood samples for platelet aggregation analysis must be 
processed within three hours of taking a patient's blood 
sample. This is achieved to eliminate platelet 
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aggregation bias. Table II shows the outcomes of Light 
Transmission Aggregometry-assisted tests. 
 
Table II: Profile of platelet aggregation with ADP as an 
inducer 
Type of platelet aggregation  n % 
Hypo-aggregation 47 89 % 
Normal aggregation 6 11 % 
Hyper-aggregation 0 0 
 
CYP2C19*3 Polymorphisms were obtained by PCR and 
electrophoresis, and the results are shown in Table III. 
 
Table III: Profile of CYP2C19*3 polymorphisms 
CYP2C19*3 polymorphisms n % 
GA 40 75 % 
GG 2 4 % 
AA 11 21 % 
 
The authors created a cross-tabulation between 
CYP2C19*3 polymorphisms and platelet aggregation. 
The result of cross-tabulation can be seen in Table IV. 
 
Table IV: Cross-tabulation between CYP2C19*3 










GA 35 5 0 
GG 2 0 0 
AA 10 1 0 
 
Discussion 
The majority of the patients in the sample were male 
(68%), with the majority of them being between the 
ages of 60 and 69. There are a number of comorbid 
conditions, the most common of which is 
hypertension. Hypertension is a risk factor for 
coronary heart disease in principle. In the presence of 
hypertension, blood vessels may cause endothelial 
damage. Endothelial dysfunction, or damage to blood 
vessels, is the first stage of atherosclerotic plaque 
development. Patients with atherosclerotic plaque 
may experience complications such as coronary heart 
disease (CHD).  According to the findings, almost all of 
the study participants had hypertension 
comorbidities, which supports the hypothesis that 
hypertension may be a cause of coronary heart 
disease. 
Platelet aggregation measurements are measured 
using light transmission aggregometry (LTA). LTA is 
also known as optical turbidimetry or aggregometry. 
This LTA can be used to identify several disorders in 
platelet defects. Despite being used as a diagnostic 
tool, LTA can also be used to measure platelet 
function (Harrison, 2000; Michelson, 2004; Rand, 
2003). 
The decrease in optical density after stimulation of 
aggregation on platelet-rich plasma is used to 
measure platelet aggregation. This approach has 
many benefits, including the fact that it has been used 
in numerous studies for a long time, is predictable, 
and the instrument can be modified. There are some 
drawbacks to the benefits, such as the fact that it 
takes a long time, the sample preparation is very 
complex, and there is no simple standardisation 
(Favaloro, 2008; Lenk, 2013).  
The agonists used in this test are ADP, collagen and 
epinephrine. Adding an agonist to this test aids to 
activate platelets. In this study, the only agonists 
observed were ADP. Clopidogrel drug inhibits platelet 
activation through inhibition of ADP binding to its 
receptors. ADP is removed from damage to blood 
vessels. ADP binding to P2Y12 receptors causes 
changes in platelet shape and induction of platelet 
aggregation through internal calcium movement. ADP 
binding to P2Y12 receptors plays a role in platelet 
aggregation response (Remijin, 2002; Koltai, 2017). 
When the number of patients is divided by the degree 
of platelet aggregation, it can be shown that the 
number of patients with hypo-aggregation is much 
higher than the number of patients with normal 
platelet aggregation. The drug's pharmacokinetic and 
pharmacodynamic effects vary from patient to 
patient. Pharmacogenomic variation, which is genetic 
variation between people, is one explanation for the 
different responses. The enzymes involved in many 
stages of metabolism, such as the phase 1 reaction or 
the phase 2 reaction in drug metabolism, have been 
studied in pharmacogenomic studies. Cytochrome 
P450 (CYP450) is an enzyme that is involved in a 
variety of metabolic processes (Cacabelos, 2012). 
Since the CYP2C group is responsible for about 20% of 
CYP450 substrate metabolism, genetic variation in 
one of the CYP2C9 classes induces different 
metabolism in certain CYP450 substrates (Speed, 
2009; Liau, 2014; Wei, 2015; Brown, 2018). 
According to the distribution of CYP2C19*3 
polymorphisms in the study set, the findings of this 
study matches with Iddrisi and the authors (2018). The 
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CYP2C19*3 polymorphism discovered was: 76.67% GA 
allele and 18.33% AA allele, according to the report. 
Due to its high prevalence relative to other enzymes, 
the CYP2C19 polymorphism is one of the most studied 
in Asian populations (Adithan, 2003; Johnson, 2011; 
Lyon, 2012; Strom, 2012). 
CYP2C19*3 is a loss-of-function allele that causes 
clopidogrel activation to be reduced. Clopidogrel 
concentrations in plasma are lower as a result of 
reduced clopidogrel activation, increasing the risk of 
platelet hyper-aggregation if plaque on the walls of 
blood vessels ruptures. As platelets hyper aggregate, 
the chances of a thrombus forming increase. The 
presence of a thrombus will result in a blockage of the 
coronary arteries, and a blockage of the coronary 
arteries is the result of ischemia. This ischemia is a 
manifestation of coronary artery disease. 
In this study, chi-square analysis calculations cannot 
be performed to see the relationship between CHD 
patients who have CYP2C19*3 polymorphisms with 
platelet aggregation because there is a value of 0. 
According to theory, a loss-of-function CYP2C19*3 
polymorphism could cause an increase in platelet 
aggregation. Clopidogrel metabolism into active 
metabolites is impaired due to CYP2C19*3 
polymorphisms. Clopidogrel's active metabolites are 
essential for inhibitors of platelet activation to bind to 
P2Y12 receptors through ADP inhibition. In this study, 
CHD patients with CYP2C19*3 polymorphisms had 
mostly hypo-aggregation of platelets, which may be 
due to the presence of more than one CYP2C19 
polymorphism in CHD patients.  
It is also important to test clopidogrel drug 
concentration in CHD patients to determine the 
activity levels of Clopidogrel in the body. In different 
races, the CYP2C19*3 polymorphism is one of the 
strong determinants of decreased Clopidogrel active 
metabolites. Clopidogrel resistance is also influenced 
by the CYP2C19*3 polymorphism (Tresukusol, 2014). 
Based on Man and Chan’s previous studies, the 
existence of CYP2C19* 3 polymorphisms has an effect 
on Clopidogrel metabolic processes in Asian patients 
undergoing PCI (Percutaneous Coronary 
Intervention). Clopidogrel metabolism effects result in 
a decline in active Clopidogrel metabolites, which may 
affect Clopidogrel's antiplatelet activity.  
Polymorphisms in the CYP2C19*2 and CYP2C19*3 
genes have been related to HPPR (High Post-
Treatment Reactivity) in another study of patients 
with the acute coronary syndrome in Asian 
populations  (Kim, 2009). Polymorphisms in the 
CYP2C19 gene are linked to high residual platelet 
reactivity, which raises the risk of major 
cardiovascular events (Yamamoto, 2011). 
The development of thrombus in the coronary arteries 
is influenced by platelet reactivity. When a platelet is 
stimulated, the coagulation pathway opens, causing 
thrombin to be released. The presence of thrombin 
causes fibrin to activate, causing the thrombus to 
mature.  
CYP2C19*3 polymorphism also has an effect on 
cardiovascular events. A study conducted by Jeong 
and the authors (2011) in patients with acute 
myocardial infarction in East Asia showed that the 
presence of CYP2C19*3 polymorphism was associated 
with an increase in cardiovascular events. Another 
study was conducted by Zhu (201)6 in patients 
undergoing Carotid Artery Stenting in Asia also 
showed a significant effect of CYP2C19*3 alleles on 
patient prognosis. Patients with CYP2C19*2 and *3 
alleles have a higher ischemic event than those 
without. 
 
Limitations of the study 
Since we did not calculate plasma concentrations of 
Clopidogrel's active metabolite, we cannot provide 
clear proof of Clopidogrel's decreased antiplatelet 
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